Valerie Heong

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Olga Kondrashova, Monique Topp, Ksenija Nesic et al. · Nature Communications · 2018 · 277 citations · Full text

Molecular correlates of platinum response in human high‐grade serous ovarian cancer patient‐derived xenografts

Monique Topp, Lynne Hartley, Michele Cook et al. · Molecular Oncology · 2014 · 138 citations · Full text

The <scp>FZD</scp>7‐<scp>TWIST</scp>1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma

Ming Tan, Asad Mohammad, Valerie Heong et al. · Molecular Oncology · 2018 · 37 citations · Full text

Fzd7 Pathway, Family Receptor 7, Cancer Biology +16

First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.

Johann S. de Bono, David S.P. Tan, Reece Caldwell et al. · Journal of Clinical Oncology · 2019 · 30 citations

Pathology, Advanced Solid Tumors, Tumor Biology +19

A multicenter phase II randomized trial of durvalumab (D) versus physician’s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).

David S.P. Tan, Chel Hun Choi, Natalie Y.L. Ngoi et al. · Journal of Clinical Oncology · 2022 · 26 citations

Medicine, Metronomic Therapy, Immunology +15